Aurigene Oncology gets DCGA nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucel

Aurigene Oncology Limited receives approval from the Drugs Controller General of India to conduct a phase-2 trial for India’s first novel BCMA-directed CAR-T cell therapy, Ribrecabtagene autoleucel. The phase-1 trial showed promising results with all patients achieving clinical response and no high-grade adverse events reported.